Synonyms: Hengqu® | SHR-8735
hetrombopag is an approved drug (China (2021))
Compound class:
Synthetic organic
Comment: Hetrombopag is an orally bioavailable, non-peptide small‐molecule thrombopoietin receptor (TPOR/MPL) agonist, that was developed as a treatment for thrombocytopenia [1]. The parent compound is shown here. It is administered as the ethanolamine/olamine.
|
|
References |
1. Xie C, Zhao H, Bao X, Fu H, Lou L. (2018)
Pharmacological characterization of hetrombopag, a novel orally active human thrombopoietin receptor agonist. J Cell Mol Med, 22 (11): 5367-5377. [PMID:30156363] |
2. Yang G, Huang R, Yang S, Zhang X, Yang X, Chen H, Huang Z, Guo C, Pei Q, Tai Y et al.. (2020)
Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers. Br J Clin Pharmacol, 86 (8): 1528-1536. [PMID:32069516] |